Product logins

Find logins to all Clarivate products below.


Venous Thromboembolism – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of VTE comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of VTE for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s VTE forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of VTE and the number of new diagnoses of VTE?
  • Of all people diagnosed with VTE, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of VTE over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following VTE subpopulations:

  • Top-line epidemiology – Diagnosed VTE events.
  • Key Populations – Diagnosed DVT events.
  • Key Populations – Diagnosed PE events.
  • Diagnosed VTE events by etiology.
  • Diagnosed VTE events by recurrence.
  • Diagnosed DVT events by treatment scheme.
  • Diagnosed PE events by treatment scheme.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
Report
Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis – China In-Depth (China)
China’s atopic dermatitis (AD) market remains grounded in established topical and systemic therapies, although limitations in longterm disease control leave a sizable unmet need among…
Report
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The U.S. wet AMD market is led by intravitreal therapies such as Eylea, Eylea HD, and Vabysmo, alongside the continued off-label use of compounded Avastin, driven by cost considerations. In…
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…